基于网络药理学和动物实验研究灵猫方治疗慢性乙型肝炎的机制

马利节; 朱晓骏; 林佳成; 王芳; 孙学华; 高月求

doi:10.3969/j.issn.1001-5256.2022.07.010

基于网络药理学和动物实验研究灵猫方治疗慢性乙型肝炎的机制

DOI: 10.3969/j.issn.1001-5256.2022.07.010

马利节^{1, 2},
朱晓骏²,
林佳成²,
王芳²,
孙学华²,
高月求^2, , ,

1.
上海中医药大学曙光临床医学院，上海 201203
2.
上海中医药大学附属曙光医院肝炎科，上海 201203

基金项目:

国家自然科学基金面上项目 (81774256);

国家自然科学基金面上项目 (81874436)

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：马利节、朱晓骏负责课题设计，资料分析，撰写论文；林佳成、王芳参与收集数据，修改论文；孙学华、高月求负责拟定写作思路，指导撰写文章并最后定稿。

详细信息

通信作者:
高月求，gaoyueqiu@hotmail.com

计量
- 文章访问数: 547
- HTML全文浏览量: 147
- PDF下载量: 70
- 被引次数: 0
出版历程
- 收稿日期: 2021-10-29
- 录用日期: 2021-12-17
- 出版日期: 2022-07-20

Mechanism of Lingmao Formula in treatment of chronic hepatitis B based on network pharmacology and animal experiment

Lijie MA^{1, 2},
Xiaojun ZHU²,
Jiacheng LIN²,
Fang WANG²,
Xuehua SUN²,
Yueqiu GAO^{2
, ,
,}

1.
Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
2.
Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

Research funding:

National Natural Science Foundation of China (81774256);

National Natural Science Foundation of China (81874436)

More Information

Corresponding author: GAO Yueqiu, gaoyueqiu@hotmail.com (ORCID: 0000-0001-7276-9810)

摘要

摘要: 目的探讨灵猫方治疗慢性乙型肝炎与Ⅰ型IFN的相关性。方法 TCMSP数据库筛选灵猫方主要活性成分；Genecards数据库获取灵猫方、慢性乙型肝炎作用靶点；Bioinformatics获取药物与疾病靶点交集、绘制韦恩图、并进行GO富集分析；DAVID 6.8进行KEGG富集分析；CytoScape 3.8.0进行免疫过程分析。30只SPF级雄性C57BL/6N小鼠，随机分为正常组、模型组、灵猫方组，每组10只，除正常组10只外，余20只采用水动力转染技术建立HBV体内复制模型，灵猫方灌胃3 d，2次/d，模型组、正常组同体积生理盐水灌胃。结束后收集血清样本，ELISA检测HBsAg、HBeAg、Ⅰ型IFN水平变化。计量资料两组间比较采用独立样本t检验，组间多重比较采用One-way ANOVA结合最小显著性差异法LSD进行多重比较分析。结果网络药理学获取灵猫方22个活性成分、6059个作用靶点，481个慢性乙型肝炎相关靶点，387个药物-疾病交集靶点，并提出灵猫方通过调控Ⅰ型IFN参与乙型肝炎相关免疫应答的假设。动物实验证实与模型组比较，灵猫方组HBsAg(t=2.227, P=0.043)、HBeAg(t=2.488, P=0.026)显著下降，且HBsAg(t=-4.603, P＜0.001)、HBeAg(t=-2.224, P=0.043)下降幅度亦具有统计学差异；与正常组相比，模型组IFNα、IFNβ水平无明显变化(P值均＞0.05)，灵猫方组IFNα、IFNβ水平显著上升(P值均＜0.001)；与模型组相比，灵猫方组IFNα、IFNβ水平亦显著上升(P值均＜0.001)。结论灵猫方通过调控Ⅰ型IFN的分泌，达到抗HBV的作用。
- 乙型肝炎, 慢性 /
- 灵猫方 /
- 网络药理学 /
- 动物实验 /
- 干扰素Ⅰ型
Abstract: Objective To investigate the association between Lingmao Formula and type Ⅰ interferon in the treatment of chronic hepatitis B. Methods TCMSP database was used to obtain the main active components of Lingmao Formula; Genecards database was used to obtain the targets of Lingmao Formula and chronic hepatitis B; Bioinformatics was used to obtain the intersection of drug targets and disease targets, plot Venn diagram, and perform GO enrichment analysis, and DAVID 6.8 was used for KEGG enrichment analysis; CytoScape 3.8.0 was used to obtain immune response-related pathways. A total of 30 specific pathogen-free male C57BL/6N mice were randomly divided into normal group, model group, and Lingmao Formula group, with 10 mice in each group. All mice except those in the normal group were used to establish a model of HBV replication in vivo by hydrodynamic transfection; the mice in Lingmao Formula group were given Lingmao Formula by gavage, twice a day for 3 days, and those in the model group and the normal group were given an equal volume of normal saline by gavage. Serum samples were collected after the experiment ended and ELISA was used to measure the changes in the levels of HBsAg, HBeAg, and type Ⅰ interferon. The independent samples t-test was used for comparison of continuous data between two groups, and one-way ANOVA combined with the least significant difference t-test was used for multiple comparisons between groups. Results Network pharmacology obtained 22 active components and 6059 action targets of Lingmao Formula, 481 targets associated with chronic hepatitis, and 387 drug-disease intersecting targets and proposed the hypothesis that Lingmao Formula participated in hepatitis B-related immune response by regulating type Ⅰ interferon. Animal experiments confirmed that compared with the model group, the Lingmao Formula group had significant reductions in HBsAg (t=2.227, P=0.043) and HBeAg (t=2.488, P=0.026), with significantly greater reductions in HBsAg (t=-4.603, P < 0.001) and HBeAg (t=-2.224, P=0.043); compared with the normal group, the model group had no significant changes in the levels of IFNα and IFNβ (P > 0.05), and the Lingmao Formula group had significant increases in the levels of IFNα and IFNβ (P < 0.001); compared with the model group, the Lingmao Formula group also had significant increases in the levels of IFNα and IFNβ (P < 0.001). Conclusion Lingmao Formula exerts an anti-HBV effect by regulating the secretion of type Ⅰ interferon.
- Hepatitis B, Chronic /
- Lingmao Formula /
- Network Pharmacology /
- Animal Experiment /
- Interferon Type Ⅰ

HTML全文

图 1 基于GeneCards数据库预测的灵猫方-CHB靶点基因交集

Figure 1. Prediction of Lingmao Formula-CHB gene intersection from GeneCards database

下载: 全尺寸图片幻灯片

图 2 灵猫方-CHB靶点基因GO及KEGG分析

注：a，灵猫方-CHB靶点基因GO分析图；b，灵猫方-CHB靶点基因KEGG分析图。

Figure 2. GO and KEGG analysis of Lingmao Formula-CHB target genes

下载: 全尺寸图片幻灯片

图 3 药物-疾病免疫过程网络

注：a，灵猫方-CHB免疫过程图；b，灵猫方-乙型肝炎免疫过程图。

Figure 3. Lingmao Formula-CHB immune process network

下载: 全尺寸图片幻灯片

表 1 灵猫方22种活性成分

Table 1. 22 active ingredients in Lingmao Formula

分子代码	活性成分	OB(%)	DL
MOL000006	木樨草素(luteolin)	36.16	0.25
MOL000098	槲皮素(quercetin)	46.43	0.28
MOL000211	丁子香萜(mairin)	55.38	0.78
MOL000354	异鼠李素(isorhamnetin)	49.60	0.31
MOL000358	β-谷甾醇(beta-sitosterol)	36.91	0.75
MOL000359	谷甾醇(sitosterol)	36.91	0.75
MOL000392	芒柄花黄素(formononetin)	69.67	0.21
MOL000398	异黄烷酮(isoflavanone)	109.99	0.30
MOL000417	毛蕊异黄酮(calycosin)	47.75	0.24
MOL000422	山柰酚(kaempferol)	41.88	0.24
MOL000433	FA	68.96	0.71
MOL000449	豆甾醇(Stigmasterol)	43.83	0.76
MOL000953	CLR	37.87	0.68
MOL001645	乙酸亚油醇酯(linoleyl acetate)	42.10	0.20
MOL001803	甜橙黄酮(sinensetin)	50.56	0.45
MOL004328	柚皮素(naringenin)	59.29	0.21
MOL004425	灵猫方苷(icariin)	41.58	0.61
MOL004427	灵猫方次甙A7(icariside A7)	31.91	0.86
MOL004576	花旗松素(taxifolin)	57.84	0.27
MOL005190	圣草酚(eriodictyol)	71.79	0.24
MOL005438	菜油甾醇(campesterol)	37.58	0.71
MOL005828	川陈皮素(nobiletin)	61.67	0.52

下载: 导出CSV

表 2 KEGG通路富集结果

Table 2. Enrichment results of KEGG pathway

ID	通路名称	基因数量	P值	基因
hsa05161	乙型肝炎	32	7.81×10^-14	PCNA, CXCL8, IFNA2, PTEN, FASLG, TNF, RELA, IFIH1, CCND1, STAT4, MAPK1, JAK1, JUN, TGFB1, IFNB1, STAT1, STAT3, MMP9, TGFBR1, NFKB1, MAVS, IL6, IRF3, IRF7, BCL2, BAX, FAS, TP53, TLR4, TLR3, TLR2, IFNAR1

下载: 导出CSV

表 3 灵猫方对HBV模型鼠HBsAg、HBeAg的影响

Table 3. Effect of Lingmao Formula on HBsAg and HBeAg in HBV model mouse

组别	动物数(只)	治疗前	治疗后	下降幅度
HBsAg(IU/mL)
模型组	10	1 813.88±590.89	1 395.43±566.21	418.45±184.63
灵猫方组	10	1 767.53±496.81	882.25±323.06	885.28±219.56
t值		0.170	2.227	-4.603
P值		0.868	0.043	＜0.001
HBeAg(S/CO)
模型组	10	58.69±12.10	29.89±5.95	28.80±9.08
灵猫方组	10	65.34±12.89	23.29±4.57	42.05±14.21
t值		-1.064	2.488	-2.224
P值		0.305	0.026	0.043

下载: 导出CSV

表 4 灵猫方对HBV模型鼠Ⅰ型IFN的影响

Table 4. Effect of Lingmao formula on typeⅠIFN in HBV model mouse

组别	动物数(只)	IFNα(ng/L)	IFNβ(ng/L)
正常组	10	49.44±13.23¹⁾	171.80±8.75¹⁾
模型组	10	54.59±10.47¹⁾	178.37±14.28¹⁾
灵猫方组	10	85.62±13.34	243.19±21.73
F值		24.838	62.052
P值		＜0.001	＜0.001
注：与灵猫方组比较，1) P＜0.001。

下载: 导出CSV

参考文献(16)

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648- 2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	CHEN BW, ZHU XJ, ZHANG X, et al. Influence of virologic response on disease progression in patients with compensated hepatitis B cirrhosis[J]. J Clin Hepatol, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014. 陈博武, 朱晓骏, 张鑫, 等. 病毒学应答状态对代偿期乙型肝炎肝硬化患者疾病进展的影响[J]. 临床肝胆病杂志, 2021, 37(8): 1811-1816. DOI: 10.3969/j.issn.1001-5256.2021.08.014.
[3]	WU L, ZHANG ZP, CAI WT, et al. Research progress on anti-hepatitis B virus activity and mechanisms of traditional Chinese medicine[J]. Chin Tradit Herb Drug, 2020, 51(24): 6367-6376. DOI: 10.7501/j.issn.0253-2670.2020.24.028. 伍磊, 张志鹏, 蔡文涛, 等. 中药抗乙肝病毒活性及作用机制的研究进展[J]. 中草药, 2020, 51(24): 6367-6376. DOI: 10.7501/j.issn.0253-2670.2020.24.028.
[4]	ZHU XJ, ZHANG X, ZHOU ZH, et al. The lingmao formula suppresses the replication of hepatitis B virus by enhancing innate immune response[J]. Chin J Integr Tradit West Med Liver Dis, 2018, 28(1): 33-36. DOI: 10.3969/j.issn.1005-0264.2018.01.012. 朱晓骏, 张鑫, 周振华, 等. 灵猫方通过增强天然免疫功能抑制乙型肝炎病毒复制的研究[J]. 中西医结合肝病杂志, 2018, 28(1): 33-36. DOI: 10.3969/j.issn.1005-0264.2018.01.012.
[5]	ZENG ZJ, LI M, SUN XH, et al. Effects of Lingmao forumla and its actions against hepatic fibrosis[J/CD]. Chin J Clinicians (Electronic Edition), 2012, 6(15): 4258-4262. DOI: 10.3877/cma.j.issn.1674-0785.2012.15.023. 曾震军, 李曼, 孙学华, 等. 中药灵猫方的抗肝纤维化作用及其机制[J/CD]. 中华临床医师杂志(电子版), 2012, 6(15): 4258-4262. DOI: 10.3877/cma.j.issn.1674-0785.2012.15.023.
[6]	ZHANG X, ZHANG XW, DING J, et al. Effects of Lingmao recipe and its single herb alcohol extract on the expression of hepatitis B surface antigen and e antigen in HepG2.2.15 cells[J]. Hebei J TCM, 2017, 39(5): 729-734. DOI: 10.3969/j.issn.1002-2619.2017.05.022. 张鑫, 张晞文, 丁俊, 等. 灵猫方及其单味药醇提物对HepG2.2.15细胞乙型肝炎表面抗原和乙型肝炎e抗原表达的影响[J]. 河北中医, 2017, 39(5): 729-734. DOI: 10.3969/j.issn.1002-2619.2017.05.022.
[7]	JIANG Y, GAO YQ, LI M, et al. Therapeutic effect of "Lingmao Decoction" combined with telbivudine in treating patients with chronic hepatitis B and the influence on the function of NK cells[J]. Acta Univ Tradit Med Sin Pharmacol Shanghai, 2017, 31(2): 16-21. DOI: 10.16306/j.1008-861x.2017.02.005. 江云, 高月求, 李曼, 等. 灵猫方联合替比夫定治疗慢性乙型肝炎患者的疗效及对NK细胞功能的影响[J]. 上海中医药大学学报, 2017, 31(2): 16-21. DOI: 10.16306/j.1008-861x.2017.02.005.
[8]	JIANG Y, GAO YQ, LI GY. Experimental study of Lingmao Formula on protecting liver and reducing enzyme in acute liver injury model[J]. Chin J Tradit Med Sci Technol, 2012, 19(5): 406-407, 384. DOI: 10.3969/j.issn.1005-7072.2012.05.014. 江云, 高月求, 李桂勇. 灵猫方对急性肝损伤模型保肝降酶作用的实验研究[J]. 中国中医药科技, 2012, 19(5): 406-407, 384. DOI: 10.3969/j.issn.1005-7072.2012.05.014.
[9]	RU J, LI P, WANG J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform, 2014, 6: 13. DOI: 10.1186/1758-2946-6-13.
[10]	LAN SH, TANG QY, LI NN, et al. Mechanism of action of Xiaochaihu decoction in the treatment of hepatitis B based on network pharmacology[J]. J Clin Hepatol, 2021, 37(10): 2308- 2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010. 蓝绍航, 唐秋媛, 李娜娜, 等. 基于网络药理学研究小柴胡汤治疗乙型肝炎的作用机制[J]. 临床肝胆病杂志, 2021, 37(10) : 2308-2315. DOI: 10.3969/j.issn.1001-5256.2021.10.010.
[11]	YONEDA M, HYUN J, JAKUBSKI S, et al. Hepatitis B virus and DNA stimulation trigger a rapid innate immune response through NF-κB[J]. J Immunol, 2016, 197(2): 630-643. DOI: 10.4049/jimmunol.1502677.
[12]	Ll FL, HUA J, LU YP, et al. Research advances in innate immunity against hepatitis B virus[J]. J Clin Hepatol, 2016, 32(5): 992-996. DOI: 10.3969/j.issn.1001-5256.2016.05.044. 李凤莉, 华娟, 卢银平, 等. HBV天然免疫的研究进展[J]. 临床肝胆病杂志, 2016, 32(5): 992-996. DOI: 10.3969/j.issn.1001-5256.2016.05.044.
[13]	BREZGIN S, KOSTYUSHEVA A, BAYUROVA E, et al. Immunity and viral infections: Modulating antiviral response via CRISPR-Cas systems[J]. Viruses, 2021, 13(7): 1373. DOI: 10.3390/v13071373.
[14]	IVASHKIV LB, DONLIN LT. Regulation of type Ⅰ interferon responses[J]. Nat Rev Immunol, 2014, 14(1): 36-49. DOI: 10.1038/nri3581.
[15]	XU F, SONG H, XIAO Q, et al. Type Ⅲ interferon-induced CBFβ inhibits HBV replication by hijacking HBx[J]. Cell Mol Immunol, 2019, 16(4): 357-366. DOI: 10.1038/s41423-018-0006-2.
[16]	LUCIFORA J, XIA Y, REISINGER F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA[J]. Science, 2014, 343(6176): 1221-1228. DOI: 10.1126/science.1243462.